Google Custom Search
Podcast Advocacy 2014 HBV Meeting navigation menu

Home

PA Biotech
Liver Cancer Connect
Visit our Baruch Blumberg Institute of Living Science
World Hepatitis Alliance Member
HepB United
Prevention and Vaccination
 

HBF Drug Watch

Compounds in Development for Chronic Hepatitis B

Updated December 15, 2014

FAMILY/DRUG NAME MECHANISM COMPANY STATUS
Interferons - Mimic naturally-occurring, infection-fighting immune substances produced in the body
Intron A
(Interferon
alfa-2b)
Immunomodulator Merck,
Whitehouse Station, NJ
FDA Approved
1991
Pegasys
(Peginterferon alfa-2a)
Immunomodulator Genentech,
South San Francisco, CA
FDA Approved 2005
There are other brands of interferon approved for HCV treatment, but they have not been FDA-approved for HBV: Wellferon (Glaxo), Roferon(Hoffman-La Roche), and Infergen (Amgen)
Nucleoside Analogues -  Interfere with the viral DNA polymerase enzyme used for hepatitis B virus reproduction
Epivir-HBV
(Lamivudine)
Inhibits viral DNA polymerase GlaxoSmithKline, Philadelphia, PA FDA Approved
1998
Hepsera
(Adefovir Dipivoxil)
Inhibits viral DNA polymerase Gilead Sciences,
Foster City, CA
FDA Approved
2002
Baraclude
(Entecavir)
Inhibits viral DNA polymerase Bristol-Myers Squibb,
Princeton, NJ
FDA Approved
2005
Tyzeka
(Telbivudine)
Inhibits viral DNA polymerase Novartis,
Switzerland
FDA Approved
2006
Viread
(Tenofovir)
Inhibits viral DNA polymerase Gilead Sciences,
Foster City, CA
FDA Approved 2008
Clevudine
(L-FMAU)
Inhibits viral DNA polymerase Bukwang,
South Korea
Eisai, Japan
Approved S. Korea
2006 (Levovir)
Tenofovir alafenamide (TAF)
Prodrug of Tenofovir Gilead Sciences,
Foster City, CA
Phase III
AGX-1009 Prodrug of Tenofovir Agenix, Australia Phase I, China
Non-Nucleoside Antivirals -  Interfere with proteins involved in viral reproduction
Myrcludex B Entry Inhibition Hepatera, Russia with Myr-GmbH, Germany Phase IIa, Russia
ARC-520 RNAi gene silencer Arrowhead Research, Pasadena, CA Phase IIa
NVR-1221
(NVR 3-778) 
Capsid inhibitor Novira Therapeutics, Doylestown, PA Phase IIa
HAP Compound
Bay 41-4109
Inhibits viral nucleocapsid AiCuris, Germany Phase I
REP 9AC     HBsAg Release Inhibitor REPLICor Inc.,
Canada
Phase I
Alinia (Nitazoxanide) Small Molecule Romark Labs,
Tampa, FL
Preclinical
dd-RNAi compound Gene silencing Benitec, Australia
and Biomics, China
Preclinical
BSBI-25 cccDNA inhibitor Baruch S. Blumberg Institute,
Doylestown, PA
Preclinical
TKM-HBV HBsAg inhibitor Tekmira,
Canada
Preclinical
ALN-HBV RNAi gene silencer

Alnylam,
Cambridge, MA

Preclinical
Birinapant
(TL32711)
SMAC inhibitor

TetraLogic,
Malvern, PA

Phase I/IIa
Non-Interferon Immune Enhancers -  Boost T-cell infection-fighting immune cells and natural interferon production
Zadaxin
(Thymosin alpha-1)
Immune stimulator SciClone
San Mateo, CA
Orphan drug approval in US for liver cancer
GS-4774 Therapeutic vaccine Gilead Sciences with Globe Immune,
Louisville, CO
Phase II
CYT107
(Interleukin-7)
Immunemodulator Cytheris,
France
Phase I/IIa
DV-601 HBV surface and core antigens Dynavax,
Berkeley, CA
Phase Ib
HBV Core Antigen Vaccine Therapeutic HBV vaccine Emergent Europe, U.K. Phase I
GS-9620 TLR7 agonist Gilead Sciences,
Foster City, CA
Phase I
Post-Exposure and/or Post-Liver Transplant Treatment
HyperHEP B S/D HBV Immuneglobulin Grifols, RTP, NC FDA Approved 1977
Nabi-HB HBV Immuneglobulin Biotest,
Boca Raton, FL
FDA Approved
1999
Hepa Gam B HBV Immuneglobulin Cangene
Canada
FDA Approved 2006

 

Page last modified December 15, 2014


donate
amazon smile

Connect with Us

facebook twitter youtube linkedin
Hep B Blog
Bookmark and Share
Site design by Ferguson Lynch  FL logo